Physician profile
Khalil Katato
NPI 1477518629
$6,501.90
in general payments reported to CMS, 2019-2025
64 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.49 · 2020: $46.18 · 2021: $430 · 2022: $907 · 2023: $1,351 · 2024: $2,106 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,109 · Consulting Fee: $525 · Education: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,108.92 |
| Consulting Fee | $525.00 |
| Education | $464.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $817.76 | 2021-2025 | Lynparza, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $795.54 | 2021-2025 | |
| Genentech USA, INC. | $361.37 | 2022-2025 | Tecentriq, Venclexta, Polivy |
| Janssen Biotech, INC. | $310.39 | 2020-2025 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $220.24 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $214.76 | 2021-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $213.71 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Pharmacyclics LLC, An Abbvie Company | $186.54 | 2021-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $185.21 | 2022-2025 | Reblozyl, Pomalyst |
| Pharmacosmos Therapeutics INC. | $176.27 | 2021-2024 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $174.80 | 2020-2025 | Onivyde, Somatuline Depot |
| Astellas Pharma US INC | $144.05 | 2023-2025 | Xospata |
| Incyte Corporation | $130.19 | 2024-2025 | Monjuvi, Jakafi, Niktimvo |
| Aveo Pharmaceuticals, INC. | $129.89 | 2023-2025 | Fotivda |
| Deciphera Pharmaceuticals INC. | $122.47 | 2021-2025 | Qinlock, Tgct |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $116.10 | 2022-2023 | Kyprolis, Blincyto |
| Genzyme Corporation | $105.33 | 2021-2024 | |
| Apellis Pharmaceuticals, INC. | $93.15 | 2022-2025 | Empaveli |
| Merck Sharp & Dohme LLC | $92.31 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Beigene USA, INC. | $89.51 | 2023-2025 | Brukinsa, Tevimbra |
| Jazz Pharmaceuticals INC. | $87.40 | 2021-2024 | |
| Kite Pharma, INC. | $87.27 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.30 | 2024-2025 | Iclusig, Fruzaqla |
| Daiichi Sankyo INC. | $82.78 | 2021-2025 | Datroway, Enhertu |
| Gilead Sciences, INC. | $79.38 | 2023-2025 | Trodelvy |
| Dendreon Pharmaceuticals LLC | $78.23 | 2022-2024 | Provenge |
| Adaptive Biotechnologies Corporation | $77.41 | 2022-2025 | Clonoseq |
| Acrotech Biopharma INC. | $76.25 | 2022-2025 | Beleodaq |
| Emd Serono, INC. | $73.55 | 2022-2025 | |
| Seagen INC. | $63.30 | 2022-2023 | Padcev, Tukysa |
| Eisai INC. | $61.96 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $56.93 | 2022-2024 | Libtayo |
| Abbvie INC. | $52.13 | 2024-2025 | |
| Lilly USA, LLC | $49.26 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Tersera Therapeutics LLC | $47.45 | 2022-2025 | Zoladex |
| Karyopharm Therapeutics INC. | $45.14 | 2022-2023 | Xpovio |
| Pharmaessentia USA Corporation | $42.61 | 2024-2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $40.31 | 2019-2022 | |
| Coherus Oncology, INC. | $39.90 | 2021 | |
| Emmaus Medical, INC. | $36.42 | 2022-2023 | Endari |
| Menarini Silicon Biosystems, INC. | $35.07 | 2025 | |
| Amag Pharmaceuticals, INC. | $34.26 | 2021 | |
| Novo Nordisk INC | $33.21 | 2022-2023 | Rebinyn, Novoseven, Novoeight |
| Stemline Therapeutics INC. | $32.69 | 2023-2025 | Orserdu |
| Geron Corporation | $31.65 | 2025 | Rytelo |
| Array Biopharma INC | $31.51 | 2025 | Braftovi, Lorbrena, Mektovi |
| Foundation Medicine, INC. | $29.09 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $25.72 | 2024 | |
| Genmab U.S., INC. | $24.37 | 2023 | Epkinly |
| Beone Medicines USA, INC. | $24.22 | 2025 | Brukinsa |
| Springworks Therapeutics, INC. | $23.55 | 2025 | |
| Mirati Therapeutics, INC. | $21.82 | 2024 | Krazati |
| Kyowa Kirin, INC. | $20.72 | 2024 | Poteligeo |
| Blueprint Medicines Corporation | $19.92 | 2025 | Ayvakit |
| Spectrum Pharmaceuticals INC. | $19.21 | 2023 | Rolvedon |
| Azurity Pharmaceuticals, INC. | $18.76 | 2025 | Danziten |
| Csl Behring | $18.59 | 2022 | |
| Rigel Pharmaceuticals, INC. | $18.57 | 2022 | |
| Recordati_rare_diseases_inc. | $18.12 | 2023 | Sylvant |
| Sumitomo Pharma America, INC. | $18.12 | 2023 | Orgovyx |
| Accord Healthcare, INC. | $17.60 | 2025 | |
| Puma Biotechnology, INC. | $16.13 | 2025 | |
| G1 Therapeutics, INC. | $15.27 | 2022 | |
| Ge Healthcare | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalil Katato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.